SpyGlass Pharma, Inc. (Nasdaq: SGP) (“SpyGlass Pharma”), a late-stage biopharmaceutical company, today announced the pricing of its initial public offering of 9,375,000 shares of its common stock at a public offering price of $16.00 per share. The aggregate gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by SpyGlass Pharma, are expected to be approximately $150 million. In addition, SpyGlass Pharma has granted the underwriters a 30-day option to purchase up to an additional 1,406,250 shares of common stock at the initial public offering price, less underwriting discounts and commissions. All shares of common stock are being offered by SpyGlass Pharma. SpyGlass Pharma’s common stock is expected to begin trading on the Nasdaq Global Select Market on February 6, 2026, under the ticker symbol “SGP.” The offering is expected to close on February 9, 2026, subject to the satisfaction of customary closing conditions.
Gilde participated in the Series D financing for Spyglass Pharma in June 2025. “We congratulate the Spyglass team on its IPO. Since our investment, we’ve been inspired by the company’s mission to improve the lives of the millions of patients with glaucoma who struggle to properly manage their disease with topical medications. This milestone is a huge step forward in bringing the company’s novel drug delivery technology to patients and we are proud to have supported them on this journey”, said Geoff Pardo, General Partner at Gilde Healthcare who serves on the Board of Directors.
Jefferies, Leerink Partners, Citigroup and Stifel are acting as joint book-running managers for the offering.
About SpyGlass Pharma
SpyGlass Pharma is a late-stage biopharmaceutical company dedicated to transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company’s mission is to significantly improve the lives of patients with chronic eye conditions by developing durable drug delivery solutions that can empower patients and surgeons with confidence in long-term disease control and vision preservation.
The SpyGlass Pharma platform, a novel, non-bioerodible drug delivery technology, is designed to be used with various well-established, approved medicines, including bimatoprost and other small molecules, providing flexibility to potentially treat a range of conditions in the front and back of the eye.
The company was founded in 2019 by Malik Y. Kahook, M.D. and Glenn Sussman to solve the lack of ophthalmic innovations that capitalize on durable treatment options. The SpyGlass Pharma platform was originally developed in the Sue Anschutz-Rodgers Eye Center at the University of Colorado Anschutz School of Medicine.
About Gilde Healthcare
Gilde Healthcare is a specialized healthcare investor managing over €3.0 billion across three fund strategies: Venture&Growth, Private Equity and Climate Solutions. The Venture&Growth fund of Gilde Healthcare invests in fast growing companies active in digital health, medtech and therapeutics, based in Europe and North America. The Private Equity fund of Gilde Healthcare participates in profitable lower mid-market healthcare companies based in North-Western Europe. The Climate Solutions fund of Gilde Healthcare partners with companies that actively address planetary challenges linked to energy transition, biodiversity loss and waste & pollution. For more information, visit the company’s website at www.gildehealthcare.com.
